1.0LGMD1D Foundation and Autosomal Dominant LGMD Registryhttps://lgmd1d.org/lgmdwpWilliam Lowery MDhttps://lgmd1d.org/lgmdwp/author/lgmd1d/LGMD and GLP-1 Drugs, 2025 - LGMD1D Foundation and Autosomal Dominant LGMD Registryrich600338<blockquote class="wp-embedded-content" data-secret="LFkMhONTuv"><a href="https://lgmd1d.org/lgmdwp/symptoms/have-symptoms-try-symptomate/">LGMD and GLP-1 Drugs, 2025</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://lgmd1d.org/lgmdwp/symptoms/have-symptoms-try-symptomate/embed/#?secret=LFkMhONTuv" width="600" height="338" title="“LGMD and GLP-1 Drugs, 2025” — LGMD1D Foundation and Autosomal Dominant LGMD Registry" data-secret="LFkMhONTuv" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://lgmd1d.org/lgmdwp/wp-includes/js/wp-embed.min.js
/* ]]> */
</script>
Short version: There’s no direct evidence that GLP-1 / GIP-GLP-1 drugs are inherently unsafe or absolutely contraindicated in LGMD, but there are very reasonable concerns about additional lean-muscle loss and frailty in someone who already has a primary myopathy. Any statement about “GLP-1 drugs in LGMD” is valid only if it’s framed as “high-caution, individualized use,” not “never use.” 1. What evidence actually exists in LGMD? I’m not finding clinical trials or case series specifically testing GLP-1 RAs or tirzepatide in LGMD. Current LGMD drug headlines are about gene therapies or other experimental agents, not GLP-1s.Synapse+1 The recent safety scare you may have seen that mentions LGMD and a patient fatality is about an LGMD gene therapy program, not about GLP-1 drugs.Prime Therapeutics+1 So any statement about GLP-1s in LGMD is, by necessity, extrapolation, not direct data. 2. What do we know about GLP-1 / GIP-GLP-1 and muscle? a) Lean mass loss is real, but proportional Across large semaglutide and tirzepatide studies: Typically ~25–35% of the weight lost is lean mass, the rest is fat. This pattern holds for tirzepatide and high-dose semaglutide (STEP, SURMOUNT and related analyses).Wiley Online Library+1 Reviews of GLP-1 RAs and sarcopenia conclude that: They…